Safety and tolerability of the β 3 ‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial-Reference-Cited by-同舟云学术

Safety and tolerability of the β 3 ‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial

Published:2014-04-06 Issue:8 Volume:68 Page:972-985
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Nitti V. W.¹,Chapple C. R.²,Walters C.³,Blauwet M. B.⁴,Herschorn S.⁵,Milsom I.⁶,Auerbach S.⁷,Radziszewski P.⁸

Affiliation:

1. Department of Urology NYU Langone Medical Center New York NY USA

2. Department of Urology Royal Hallamshire Hospital Sheffield UK

3. Astellas Pharma Europe Ltd Chertsey Surrey UK

4. Department of Biostatistics Astellas Pharma Global Development Northbrook IL USA

5. Department of Urology University of Toronto Toronto Canada

6. Department of Obstetrics and Gynecology Sahlgrenska Academy Gothenburg University Gothenburg Sweden

7. Hoag Memorial Presbyterian Hospital Newport Beach CA USA

8. Department of Urology Medical University Warsaw Warsaw Poland

Funder

Astellas

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.12433

Reference50 articles.

1. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction

2. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study

3. A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results from the EPIC Study

4. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

5. Antimuscarinics for treatment of overactive bladder

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on Therapies in Older Adults;Medical Clinics of North America;2024-09

2. Brown adipose tissue-derived metabolites and their role in regulating metabolism;Metabolism;2024-01

3. Personalized approach to pharmacotherapy of overactive bladder;Urology reports (St. - Petersburg);2023-11-17

4. Distinct Conformations of Mirabegron Determined by MicroED;Advanced Science;2023-10-17

5. Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study;Frontiers in Oncology;2023-05-02